In murine tumor models, the integration of RT with anti-PD-1 or anti-PD-L1 monoclonal antibodies induces significant CD8+ T cell responses, enhancing local tumor control, extending survival, and improving resistance to tumor rechallenge [90]. Here, PDCD1 is linked to neoplasm.